ClinicalTrials.gg
RecruitingNCT05176483STELLAR-002Updated Oct 1, 2026

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

A Phase 1 interventional study of Zanzalintinib and Nivolumab in Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Urothelial Carcinoma (UC), sponsored by Exelixis. Recruiting at 122 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Exelixis · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2021; still recruiting 4 years 11 months later.
Updated Oct 1, 2026Site recruiting status changedInterventions changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
1,394
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing zanzalintinib in Carcinoma, Renal Cell — 10 open to participants now, 12 under way, 4 of them phase 3. zanzalintinib · Carcinoma, Renal Cell.

Planned enrollment
2nd of 13
1,394 · median 140
Started
2021
the only one that year
Phase 1
3 of 13
1 open now
Primary completion
2027-01
later than 2 of 11 live
Registered
2nd of 13
by date
Lead sponsor
5 of 13
Exelixis

Among the 13 studies testing zanzalintinib in Carcinoma, Renal Cell, this one is the 2nd largest by planned enrollment, is the only one that started in 2021, is one of 3 in phase 1, reaches primary completion later than 2 of the 11 other live ones, and was the 2nd registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

10 of the 13 studies testing zanzalintinib in Carcinoma, Renal Cell are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About zanzalintinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing zanzalintinib in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) and in combination with docetaxel and prednisone in participants with advanced solid tumors. In addition, the study will evaluate the effect of multiple dose administration of zanzalintinib on the single-dose pharmacokinetics of sensitive CYP3A4, CYP2C9, CYP2C19, or CYP1A2 substrates in participants with advanced solid tumors.

In the Expansion Stage, the safety and efficacy of zanzalintinib as monotherapy and in combination therapy will be further evaluated in tumor-specific Expansion Cohorts.

03

Conditions studied

  • Renal Cell Carcinoma (RCC)
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Urothelial Carcinoma (UC)
  • Solid Tumor
  • Hepatocellular Carcinoma (HCC)
  • Non-small Cell Lung Cancer (NSCLC)
  • Colorectal Cancer (CRC)
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Clear Cell Renal Cell Carcinoma (ccRCC)
  • Non-Clear Cell Renal Cell Carcinoma (nccRCC)
  • Drug-Drug Interaction (DDI)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • or histologically confirmed solid tumor that is unresectable, locally advanced or .
  • Dose-Escalation Cohorts: Participants with a solid tumor that is unresectable or metastatic and for which life-prolonging therapies do not exist or available therapies are intolerable or no longer effective.
  • Expansion Cohort 1 (ccRCC): Participants with unresectable advanced or metastatic RCC with a clear cell component who have not received prior systemic therapy.

    • Note: Prior non-vascular endothelial growth factor (VEGF) targeted adjuvant or is allowed if disease recurrence occurred 6 months after the last dose.
  • Expansion Cohort 2 (ccRCC): Participants with unresectable advanced or metastatic RCC with a clear cell component.

    • Must have radiographically progressed after a combination therapy consisting of a Programmed Cell Death Protein 1 ()/Programmed death-ligand 1 (PD-L1) targeting monoclonal antibody (mAb) with a Vascular endothelial growth factor (receptor) tyrosine kinase inhibitor (VEGFR-TKI) or a PD-1 targeting mAb with a CTLA-4 mAb as the preceding .
    • Must have received no more than one prior systemic anticancer therapy for unresectable advanced or metastatic renal cell carcinoma.
  • Expansion Cohort 3 (mCRPC): Men with metastatic adenocarcinoma of the prostate.

    • Must have progressed during or after one novel hormone therapy (NHT) given for castration-sensitive locally advanced (T3 or T4) or metastatic castration-sensitive prostate cancer (CSPC), M0 CRPC, or mCRPC.
  • Expansion Cohort 4 (UC, ICI-naive): Participants with histologically confirmed unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (including the renal pelvis, ureter, urinary bladder, or urethra).

    • Must have progressed during or after prior first-line platinum-based combination therapy, including participants who received prior neoadjuvant or adjuvant platinum-containing therapy with disease recurrence \< 12 months from the end of last therapy.
    • Must have received no more than 1 prior line of systemic anticancer therapy for unresectable, locally advanced or metastatic disease.
  • Expansion Cohort 5 (post enfortumab vedotin [EV] and ICI): Participants with histologically confirmed unresectable, locally advanced or metastatic predominant urothelial carcinoma.

    • Progressive disease following prior EV or ineligible for EV, and progression following prior PD-1/PD-L1 inhibitor or ineligible for PD-1/PD-L1 inhibitor.
    • Prior receipt of platinum-based therapy allowed but not required.
    • Prior therapy with other agents allowed but not required.
  • Expansion Cohort 6 (nccRCC): Participants with unresectable advanced or metastatic nccRCC of the following subtypes: Papillary, unclassified RCC, and translocation-associated, Fumarate Hydratase (FH) deficient and Succinate Dehydrogenase (SDH) deficient. Among the eligible histologic subtypes, sarcomatoid features are allowed.

    • No prior systemic anticancer therapy is allowed except adjuvant or neoadjuvant therapy if disease recurrence occurred at least 6 months after the last dose.
  • Expansion Cohort 7 (HCC): Participants with locally advanced, or metastatic and/or unresectable HCC that is not amenable to curative treatment or locoregional therapy.
  • Expansion Cohort 8 (NSCLC): Participants with Stage IV non-squamous NSCLC with positive PD-L1 expression (tumor proportion score [TPS] 1-49%) and without prior systemic anticancer therapy for metastatic disease.
  • Expansion Cohort 9 (NSCLC): Participants with Stage IV non-squamous NSCLC who have radiologically progressed following treatment with one prior immune checkpoint inhibitor (anti-PD-1 or anti-PD-L1) for metastatic disease.
  • Expansion Cohort 10 (CRC): Participants with histologically confirmed unresectable, locally advanced, or metastatic adenocarcinoma of the colon or rectum.
  • Expansion Cohort 11 (HNSCC): Participant with inoperable, , recurrent or metastatic HNSCC of the oral cavity, oropharynx, hypopharynx, and larynx. PD-L1 combined positive score (CPS) ≥1.
  • Expansion Cohort 12 (ccRCC): Participants with unresectable advance or metastatic RCC with a clear cell component, including participants who also have a sacromatoid feature.

    • Must have received no more than two prior lines of systemic anticancer therapy for unresectable advanced or metastatic renal cell carcinoma
  • Expansion Cohort 13 and Cohort 14 (ccRCC 1L): Participants with unresectable advanced or metastatic RCC with a clear component, including participants who also have a sacromatoid feature.
  • Cohort 15 (mCRPC, post-ARPI, visceral metastases): Men with metastatic adenocarcinoma of the prostate.
  • Cohort 16 (Drug-drug interaction [DDI]):

    • Participants with a solid tumor that is unresectable or metastatic and for which life prolonging therapies do not exist or available therapies are intolerable or no longer effective.
    • Able to swallow capsules or tablets.
  • For all Expansion Cohorts except Cohort 3: per 1.1 as determined by the Investigator.
  • For Expansion Cohorts 1 - 11 Only: material, if available, or fresh tumor tissue if it can be safely obtained.
  • Recovery to baseline or ≤ Grade 1 (CTCAE) v5 from AE(s) related to any prior treatments unless AE(s) are deemed clinically nonsignificant by the Investigator and/or stable on supportive therapy.
  • Performance Status (KPS) ≥ 70%.
  • Adequate organ and marrow function.
  • Sexually active fertile participants and their partners must agree to use highly effective methods of .
  • Females of must not be pregnant at screening.

Key Exclusion Criteria:

  • For all Dose-Escalation cohorts: Prior treatment with zanzalintinib. For all Expansion Cohorts: Prior treatment with zanzalintinib, nivolumab, ipilimumab or relatlimab with the following exceptions: Prior PD-1/PD-L1, Lymphocyte-activation gene 3 (LAG-3) and cytotoxic T lymphocyte associated protein 4 (CTLA-4) targeting therapy for locally advanced or metastatic disease is allowed for Cohort 2 (ccRCC), Cohort 5 (UC), Cohort 9 (NSCLC), and Cohort 12 (ccRCC), and prior treatment in the neoadjuvant or adjuvant setting is allowed for Cohort 13 and Cohort 14 (ccRCC 1L).
  • For all Dose-Escalation Cohorts and Expansion Cohort 2 (ccRCC), 3 (mCRPC), Cohort 5 (UC), Cohort 9 (NSCLC), Cohort 10 (CRC), and Cohort 12: Receipt of any type of small molecule kinase inhibitor (including kinase inhibitor) within 2 weeks before first dose of study treatment.
  • For Cohort 3 (mCRPC): Receipt of abiraterone within 1 week; cyproterone within 10 days; or receipt of flutamide, nilutamide, bicalutamide, enzalutamide, or other androgen receptor inhibitors within 2 weeks before first dose of study treatment.
  • For all Dose-Escalation Cohorts and Expansion Cohort 2 (ccRCC), Cohort 3 (mCRPC), Cohort 5 (UC), Cohort 9 (NSCLC) and Cohort 10 (CRC), and Cohort 12: Receipt of any type of anticancer antibody or systemic chemotherapy within 4 weeks before first dose of study treatment.
  • Any complementary medications (eg, herbal supplements or traditional Chinese medicines) to treat the disease under study within 2 weeks before first dose of study treatment.
  • Prior external radiation therapy for bone metastasis within 2 weeks, for other tumor sites within 4 weeks, and prior radium-223 therapy within 6 weeks before first dose of study treatment, unless otherwise specified.
  • Known or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment.
  • Concomitant anticoagulation with oral anticoagulants, except for specified direct factor Xa inhibitors.
  • Administration of a live, attenuated vaccine within 30 days prior to first dose.
  • Uncontrolled, significant intercurrent or recent illness.
  • interval calculated by the Fridericia formula (QTcF) > 460 ms for females and > 450 ms for males per (ECG) within 14 days before first dose of study treatment.
  • Participants with inadequately treated adrenal insufficiency.
  • Pregnant or lactating females.
  • Any other active within two years before first dose of study treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with systemic therapy. Incidentally diagnosed prostate cancer is allowed if assessed as stage ≤ T2N0M0 and Gleason score ≤ 6.
  • For Cohort 2 (ccRCC, 2L): Receipt of a prior triplet therapy including a VEGFR-TKI, a PD1 targeting mAb, and a CTLA-4 mAb.
  • For Cohort 3 (mCRPC): Receipt of a taxane-based chemotherapy for mCRPC.
  • For Cohort 4 (UC, ICI-naïve): Participants who have had recurrence within the 6 months of completing adjuvant anti-PD-(L)1 treatment.
  • For Cohort 6 (nccRCC, 1L): Participants with chromophobe, renal medullary carcinoma, or pure collecting duct nccRCC.
  • For Cohort 7 (HCC):

    • Documented hepatic encephalopathy (HE) within 6 months before the first dose.
    • ascites (ie, ascites requiring paracentesis or escalation in diuretics) within 6 months before randomization.
    • Participants who have received any local anticancer therapy including surgery, percutaneous ethanol injection (PEI), radiofrequency ablation (RFA), microwave ablation (MWA), transarterial chemoembolization (TACE), or transarterial radioembolization (TARE) within 28 days prior to first dose.
    • Participants with known fibrolamellar carcinoma, sarcomatoid HCC, or mixed hepatocellular cholangiocarcinoma
  • For Cohort 10 (CRC, 2L+): Receipt of prior therapy with regorafenib and/or trifluridine + tipiracil (TAS-102).
  • For Cohort 11 (HNSCC): Primary tumor site of the nasopharyngeal area.
  • For Cohorts 1 (ccRCC, 1L), 2 (ccRCC, 2L), 4, 5 (UC), 7 (HCC), 8 (NSCLC 1L PD-L1 low), 9 (NSCLC, 2L+), 10 (CRC, microsatellite stable [MSS], 2L+), and 11 (HNSCC):

    • Troponin T (TnT) or I (TnI) > 2 × institutional (ULN).
  • For Cohort 16 (DDI):

    • Known to midazolam, warfarin, omeprazole, or caffeine.
    • History of major head trauma (with loss of consciousness) within the past year or minor head trauma (without loss of consciousness) within 3 months prior to first dose of study treatment on Day 1.
    • Primary liver tumor.
    • Unable to refrain from or anticipates the use of the following:

      • Any drugs known to be inducers or inhibitors of , CYP2C9, CYP2C19, and/or CYP1A2 within 14 days before the first dose of study treatment on Day 1 through the DDI assessments on Day 20.
      • Drugs that are with midazolam, warfarin, omeprazole, and/or caffeine during the DDI assessment part.
      • Caffeine-containing beverages, products, and foods at least 3 days prior to and 3 days after probe substrate cocktail administration on Day 1 and Day 16.

        • Poor peripheral venous access.

Note: Additional Inclusion and Exclusion criteria may apply.

Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
1,394 participants (estimated)

Study arms

  • Experimental
    Zanzalintinib + Nivolumab Dose-Escalation Cohorts

    Approximately 12 participants will accrue across 1-2 dose levels of Zanzalintinib following the "rolling 6" design.

    Drug: Zanzalintinib · Drug: Nivolumab

  • Experimental
    Zanzalintinib + Nivolumab + Ipilimumab Dose-Escalation Cohorts

    Approximately 12 participants will accrue across 1-2 dose levels of Zanzalintinib following the "rolling 6" design.

    Drug: Zanzalintinib · Drug: Nivolumab · Drug: Ipilimumab

  • Experimental
    Zanzalintinib + Nivolumab Expansion Cohorts

    The recommended dose from the dose-escalation stage may be further explored in tumor-specific cohorts.

    Drug: Zanzalintinib · Drug: Nivolumab

  • Experimental
    Zanzalintinib + Nivolumab + Ipilimumab Expansion Cohorts

    The recommended dose from the dose-escalation stage may be further explored in tumor-specific cohorts.

    Drug: Zanzalintinib · Drug: Nivolumab · Drug: Ipilimumab

  • Experimental
    Zanzalintinib Single-Agent Expansion Cohorts

    Drug: Zanzalintinib

  • Experimental
    Zanzalintinib + Nivolumab + Relatlimab Dose-Escalation Cohorts

    Approximately 12 participants will accrue across 1-2 dose levels of Zanzalintinib following the "rolling 6" design.

    Drug: Zanzalintinib · Drug: Nivolumab + Relatlimab

  • Experimental
    Zanzalintinib + Nivolumab + Relatlimab Expansion Cohorts

    The recommended dose from the dose-escalation stage may be further explored in tumor-specific cohorts.

    Drug: Zanzalintinib · Drug: Nivolumab + Relatlimab

  • Experimental
    Zanzalintinib + Docetaxel + Prednisone Dose Expansion Cohort

    Participants with mCRPC, post-androgen receptor pathway inhibitor (post-ARPI), visceral metastases. The recommended dose from the dose-escalation stage may be further explored in tumor-specific cohorts.

    Drug: Zanzalintinib · Drug: Prednisone · Drug: Docetaxel

  • Experimental
    Zanzalintinib + DDI Probe Substrates Dose Expansion Cohort

    Participants in the DDI Cohort. The recommended dose from the dose-escalation stage may be further explored in tumor-specific cohorts.

    Drug: Zanzalintinib · Drug: DDI Probe Cocktail

Interventions

  • Zanzalintinib orally once daily (qd)

    Also known as: XL092

  • 360 mg intravenous (IV) infusion once every 3 weeks (q3w)

    Also known as: Opdivo

  • 1 mg/kg IV infusion once every 3 weeks (q3w) for maximum of four doses

    Also known as: Yervoy

  • DrugNivolumab + Relatlimab

    Drug pages: Nivolumab · Relatlimab

    IV administration of nivolumab + relatlimab

  • Administered as IV infusion.

  • Administered as oral tablet.

  • DrugDDI Probe Cocktail

    Midazolam, Warfarin, Omeprazole, and Caffeine administered orally.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Including Immune-Mediated Adverse Events (imAEs)

    Time frame: Up to 36 months

  2. Expansion Stage (All Cohorts Except Cohort 15 [mCRPC, post-ARPI, visceral metastases] and Cohort 16 [DDI]): Objective Response Rate (ORR)

    As assessed by the Investigator per Response Evaluation Criteria in Solid Tumors guideline version 1.1 (RECIST 1.1).

    Time frame: Up to 24 months

  3. Expansion Stage Cohort 3 (mCRPC, post 1 NHT): Progression-Free Survival (PFS)

    As assessed by the Investigator per RECIST 1.1.

    Time frame: Up to 24 months

  4. Expansion Stage Cohort 10 (CRC): Overall Survival (OS)

    Time frame: 6 months

  5. Expansion Stage Cohort 15 (mCRPC, Post-ARPI, Visceral Metastases): PFS-6 (Six Month PFS)

    As assessed by the Investigator per RECIST 1.1.

    Time frame: 6 months

  6. Expansion Stage Cohort 16 (DDI): Area Under the Concentration-Versus-Time Curve (AUC) of Each DDI Probe Substrate With and Without Zanzalintinib

    Time frame: Predose upto 8 hours postdose

  7. Expansion Stage Cohort 16 (DDI): Maximum Concentration (Cmax) of Each DDI Probe Substrate With and Without Zanzalintinib

    Time frame: Predose upto 8 hours postdose

Secondary outcomes

  1. Expansion Stage (All Cohorts Except Cohort 16 [DDI]): Duration of Response (DOR)

    To evaluate DOR in participants with measurable disease as assessed by the Investigator per RECIST 1.1.

    Time frame: Up to 24 months

  2. Expansion Stage (All Cohorts Except Cohort 16 [DDI]): Progression-Free Survival (PFS)

    As assessed by the Investigator per RECIST 1.1.

    Time frame: Up to 24 months

  3. Expansion Stage Cohort 15 (mCRPC, Post-ARPI, Visceral Metastases): PFS-12 (12 Month PFS)

    As assessed by the Investigator per RECIST 1.1.

    Time frame: 12 months

  4. Expansion Stage Cohort 15 (mCRPC, Post-ARPI, Visceral Metastases): Prostate-Specific Antigen 50% Response Rate (PSA50-RR)

    Time frame: Up to 24 months

  5. Expansion Stage Cohort 15 (mCRPC, Post-ARPI, Visceral Metastases): ORR

    As assessed by the Investigator per RECIST 1.1.

    Time frame: 12 months

  6. Expansion Stage Cohort 15 (mCRPC, Post-ARPI, Visceral Metastases): AUC of Zanzalintinib

    Time frame: Predose upto 8 hours postdose

  7. Expansion Stage Cohort 15 (mCRPC, Post-ARPI, Visceral Metastases): AUC of Docetaxel

    Time frame: Predose upto 8 hours postdose

07

Study locations

101 of 122 sites recruiting
  • Exelixis Clinical Site #67
    Phoenix, Arizona 85054, United States
    Recruiting
  • Exelixis Clinical Site #1
    Tucson, Arizona 85711, United States
    Recruiting
  • Exelixis Clinical Site #123
    Palo Alto, California 94304, United States
    Completed

    Not enrolling at this site — choose another above.

  • Exelixis Clinical Site #59
    Santa Barbara, California 93463, United States
    Recruiting
  • Exelixis Clinical Site #87
    Littleton, Colorado 80124, United States
    Recruiting
  • Exelixis Clinical Site #62
    New Haven, Connecticut 06510, United States
    Recruiting
  • Exelixis Clinical Site #49
    Newark, Delaware 19713, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Exelixis Clinical Site #48
    Celebration, Florida 34747, United States
    Recruiting
  • Exelixis Clinical Site #11
    Gainesville, Florida 32610, United States
    Recruiting
  • Exelixis Clinical Site #78
    Jacksonville, Florida 32224, United States
    Recruiting
  • Exelixis Clinical Site #47
    Miami, Florida 33136, United States
    Recruiting
  • Exelixis Clinical Site #61
    Plantation, Florida 33322, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Exelixis Clinical Site #8
    Tampa, Florida 33612, United States
    Recruiting
  • Exelixis Clinical Site #26
    Chicago, Illinois 60612, United States
    Recruiting
  • Exelixis Clinical Site #4
    Indianapolis, Indiana 46250, United States
    Recruiting
  • Exelixis Clinical Site #122
    Louisville, Kentucky 40202, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Exelixis Clinical Site #14
    Baltimore, Maryland 21201, United States
    Recruiting
  • Exelixis Clinical Site #7
    Boston, Massachusetts 02215, United States
    Recruiting
  • Exelixis Clinical Site #65
    Detroit, Michigan 48201, United States
    Recruiting
  • Exelixis Clinical Site #13
    Detroit, Michigan 48202, United States
    Recruiting
  • Exelixis Clinical Site #68
    Rochester, Minnesota 55905, United States
    Recruiting
  • Exelixis Clinical Site #2
    Omaha, Nebraska 68130, United States
    Recruiting
  • Exelixis Clinical Site #5
    Omaha, Nebraska 68130, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Exelixis Clinical Site #55
    Las Vegas, Nevada 89052, United States
    Recruiting
  • Exelixis Clinical Site #88
    East Brunswick, New Jersey 08816, United States
    Recruiting
  • Exelixis Clinical Site #105
    Hackensack, New Jersey 07601, United States
    Recruiting
  • Exelixis Clinical Site #60
    New York, New York 10032, United States
    Recruiting
  • Exelixis Clinical Site #6
    New York, New York 10065, United States
    Recruiting
  • Exelixis Clinical Site #76
    Syracuse, New York 13210, United States
    Recruiting
  • Exelixis Clinical Site #12
    Durham, North Carolina 27710, United States
    Recruiting
  • Exelixis Clinical Site #10
    Cleveland, Ohio 44106, United States
    Recruiting
  • Exelixis Clinical Site #51
    Portland, Oregon 97239, United States
    Recruiting
  • Exelixis Clinical Site #104
    Hershey, Pennsylvania 17033, United States
    Recruiting
  • Exelixis Clinical Site #98
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Exelixis Clinical Site #32
    Pittsburgh, Pennsylvania 15212, United States
    Recruiting
  • Exelixis Clinical Site #24
    Pittsburgh, Pennsylvania 15232, United States
    Completed

    Not enrolling at this site — choose another above.

  • Exelixis Clinical Site #9
    Myrtle Beach, South Carolina 29572, United States
    Recruiting
  • Exelixis Clinical Site #3
    Nashville, Tennessee 37203, United States
    Recruiting
  • Exelixis Clinical Site #46
    Austin, Texas 78705, United States
    Recruiting
  • Exelixis Clinical Site #111
    Dallas, Texas 75246, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Exelixis Clinical Site #89
    Dallas, Texas 75246, United States
    Recruiting
  • Exelixis Clinical Site #73
    Irving, Texas 75063, United States
    Recruiting
  • Exelixis Clinical Site #50
    Plano, Texas 75075, United States
    Recruiting
  • Exelixis Clinical Site #70
    Tyler, Texas 75601, United States
    Recruiting
  • Exelixis Clinical Site #66
    Charlottesville, Virginia 22903, United States
    Recruiting
  • Exelixis Clinical Site #33
    Milwaukee, Wisconsin 53226, United States
    Recruiting
  • Exelixis Clinical Site #116
    Albury, 2640, Australia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Exelixis Clinical Site #35
    Birtinya, 4575, Australia
    Recruiting
  • Exelixis Clinical Site #16
    Brisbane, 4102, Australia
    Recruiting
  • Exelixis Clinical Site #42
    Saint Leonards, 2065, Australia
    Recruiting
  • Exelixis Clinical Site #36
    Sydney, 2109, Australia
    Recruiting
  • Exelixis Clinical Site #94
    Graz, 8036, Austria
    Recruiting
  • Exelixis Clinical Site #31
    Salzburg, 5020, Austria
    Completed

    Not enrolling at this site — choose another above.

  • Exelixis Clinical Site #29
    Vienna, 1020, Austria
    Recruiting
  • Exelixis Clinical Site #106
    Wein, 1090, Austria
    Recruiting
  • Exelixis Clinical Site #39
    Anderlecht, 1070, Belgium
    Completed

    Not enrolling at this site — choose another above.

  • Exelixis Clinical Site #37
    Kortrijk, 8500, Belgium
    Recruiting
  • Exelixis Clinical Site #85
    Besançon, 25030, France
    Recruiting
  • Exelixis Clinical Site #96
    Bordeaux, 33000, France
    Recruiting
  • Exelixis Clinical Site #79
    Caen, 14076, France
    Recruiting
  • Exelixis Clinical Site #118
    Clermont-Ferrand, 63011, France
    Recruiting
  • Exelixis Clinical Site #109
    Lyon, 69008, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Exelixis Clinical Site #92
    Marseille, 13273, France
    Recruiting
  • Exelixis Clinical Site #64
    Nice, 06189, France
    Recruiting
  • Exelixis Clinical Site #83
    Paris, 75010, France
    Recruiting
  • Exelixis Clinical Site #91
    Paris, 75015, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Exelixis Clinical Site #80
    Rennes, 35042, France
    Recruiting
  • Exelixis Clinical Site #63
    Saint-Herblain, 44805, France
    Recruiting
  • Exelixis Clinical Site #75
    Strasbourg, 67200, France
    Completed

    Not enrolling at this site — choose another above.

  • Exelixis Clinical Site #84
    Vandœuvre-lès-Nancy, 54519, France
    Recruiting
  • Exelixis Clinical Site #115
    Villejuif, 94805, France
    Recruiting
  • Exelixis Clinical Site #103
    Essen, 45147, Germany
    Recruiting
  • Exelixis Clinical Site #113
    Hamburg, 22763, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Exelixis Clinical Site #108
    Heidelberg, 69120, Germany
    Recruiting
  • Exelixis Clinical Site #82
    Herne, 44625, Germany
    Completed

    Not enrolling at this site — choose another above.

  • Exelixis Clinical Site #93
    Jena, 07747, Germany
    Recruiting
  • Exelixis Clinical Site #112
    München, 81737, Germany
    Completed

    Not enrolling at this site — choose another above.

  • Exelixis Clinical Site #102
    Nürtingen, 72622, Germany
    Recruiting
  • Exelixis Clinical Site #107
    Trier, 54292, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Exelixis Clinical Site #95
    Tübingen, 72076, Germany
    Recruiting
  • Exelixis Clinical Site #86
    Beersheba, 8410101, Israel
    Recruiting
  • Exelixis Clinical Site #72
    Haifa, 3109601, Israel
    Recruiting
  • Exelixis Clinical Site #52
    Jerusalem, 9112001, Israel
    Withdrawn

    Not enrolling at this site — choose another above.

  • Exelixis Clinical Site #71
    Petah Tikva, 4941492, Israel
    Recruiting
  • Exelixis Clinical Site #69
    Tel Aviv, 6423906, Israel
    Recruiting
  • Exelixis Clinical Site #38
    Ẕerifin, 7030000, Israel
    Recruiting
  • Exelixis Clinical Site #121
    Ancona, 60020, Italy
    Recruiting
  • Exelixis Clinical Site #117
    Bologna, 40138, Italy
    Recruiting
  • Exelixis Clinical Site #90
    Florence, 50134, Italy
    Recruiting
  • Exelixis Clinical Site #101
    Milan, 20132, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Exelixis Clinical Site #81
    Milan, 20141, Italy
    Recruiting
  • Exelixis Clinical Site #40
    Naples, 80131, Italy
    Recruiting
  • Exelixis Clinical Site #74
    Ravenna, 48121, Italy
    Recruiting
  • Exelixis Clinical Site #30
    Grafton, 1023, New Zealand
    Recruiting
  • Exelixis Clinical Site #45
    Hamilton, 3204, New Zealand
    Recruiting
  • Exelixis Clinical Site #20
    Bydgoszcz, 85-796, Poland
    Recruiting
  • Exelixis Clinical Site #28
    Gdansk, 80-219, Poland
    Recruiting
  • Exelixis Clinical Site #34
    Otwock, 05-400, Poland
    Recruiting
  • Exelixis Clinical Site #54
    Poznan, 60-569, Poland
    Recruiting
  • Exelixis Clinical Site #114
    Wroclaw, 53-413, Poland
    Recruiting

Showing the first 100 of 122 sites across 13 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Jan 2027, 61 months after the start.

Of 138 industry-sponsored phase 1 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's planned 61 months is above that.

Counting every sponsor, half of 220 studies reached it within 50 months; a quarter within 32 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2021
First posted
Jan 4, 2022
StartActual
Dec 14, 2021
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jun 28, 2030
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
13 sites changed recruiting status (9 now withdrawn, 4 now completed)
Show 13 sites
  • Exelixis Clinical Site #123 · Palo Alto, United StatesRecruiting→Completed
  • Exelixis Clinical Site #61 · Plantation, United StatesRecruiting→Withdrawn
  • Exelixis Clinical Site #122 · Louisville, United StatesRecruiting→Withdrawn
  • Exelixis Clinical Site #24 · Pittsburgh, United StatesRecruiting→Completed
  • Exelixis Clinical Site #111 · Dallas, United StatesRecruiting→Withdrawn
  • Exelixis Clinical Site #116 · Albury, AustraliaRecruiting→Withdrawn
  • Exelixis Clinical Site #75 · Strasbourg, FranceRecruiting→Completed
  • Exelixis Clinical Site #113 · Hamburg, GermanyRecruiting→Withdrawn
  • Exelixis Clinical Site #82 · Herne, GermanyRecruiting→Completed
  • Exelixis Clinical Site #107 · Trier, GermanyRecruiting→Withdrawn
  • Exelixis Clinical Site #52 · Jerusalem, IsraelRecruiting→Withdrawn
  • Exelixis Clinical Site #101 · Milan, ItalyRecruiting→Withdrawn
  • Exelixis Clinical Site #120 · L'Hospitalet de Llobregat, SpainRecruiting→Withdrawn
Oct 1, 2026
Interventions
Removed Drug: Nivolumab
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    13 sites changed recruiting status (9 now withdrawn, 4 now completed)
    Show 13 sites
    • Exelixis Clinical Site #123 · Palo Alto, United StatesRecruiting→Completed
    • Exelixis Clinical Site #61 · Plantation, United StatesRecruiting→Withdrawn
    • Exelixis Clinical Site #122 · Louisville, United StatesRecruiting→Withdrawn
    • Exelixis Clinical Site #24 · Pittsburgh, United StatesRecruiting→Completed
    • Exelixis Clinical Site #111 · Dallas, United StatesRecruiting→Withdrawn
    • Exelixis Clinical Site #116 · Albury, AustraliaRecruiting→Withdrawn
    • Exelixis Clinical Site #75 · Strasbourg, FranceRecruiting→Completed
    • Exelixis Clinical Site #113 · Hamburg, GermanyRecruiting→Withdrawn
    • Exelixis Clinical Site #82 · Herne, GermanyRecruiting→Completed
    • Exelixis Clinical Site #107 · Trier, GermanyRecruiting→Withdrawn
    • Exelixis Clinical Site #52 · Jerusalem, IsraelRecruiting→Withdrawn
    • Exelixis Clinical Site #101 · Milan, ItalyRecruiting→Withdrawn
    • Exelixis Clinical Site #120 · L'Hospitalet de Llobregat, SpainRecruiting→Withdrawn
    Interventions Removed Drug: Nivolumab
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05176483
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
Jan 4, 2022
Start date
Dec 14, 2021
Primary completion
Jan 31, 2027 (estimated)
Completion
Jun 28, 2030 (estimated)
Last update
Oct 1, 2026

Study contacts

Exelixis Clinical Trials
Contact
druginfo@exelixis.com
1-888-EXELIXIS (888-393-5494)
Backup or International
Contact
650-837-7400
Medical Director
study director · Exelixis

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanzalintinib

Start the discussion